AR037770A1 - Compuesto inhibidor de la integrasa del vih, composicion farmaceutica que lo comprende y uso del mismo para prepararla - Google Patents
Compuesto inhibidor de la integrasa del vih, composicion farmaceutica que lo comprende y uso del mismo para prepararlaInfo
- Publication number
- AR037770A1 AR037770A1 ARP020104777A ARP020104777A AR037770A1 AR 037770 A1 AR037770 A1 AR 037770A1 AR P020104777 A ARP020104777 A AR P020104777A AR P020104777 A ARP020104777 A AR P020104777A AR 037770 A1 AR037770 A1 AR 037770A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- independently selected
- co2r5
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 21
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 -O-aryl Chemical group 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 108010002459 HIV Integrase Proteins 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
- C07C207/04—Compounds containing nitroso groups bound to a carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/63—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton
- C07C255/64—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una composición farmacéutica útil para el tratamiento de infecciones por VIH, que comprende una cantidad terapéutica del compuesto de la fórmula (1) y un portador farmacéuticamente aceptable, la cual puede comprender además una cantidad terapéuticamente efectiva de uno o más de otros agentes para el tratamiento del VIH. Uso de un compuesto de la fórmula (1) o una sal o solvato farmacéuticamente aceptable del mismo, para preparar una composición farmacéutica para inhibir la integrasa de VIH o para aplicar en el tratamiento de una infección por VIH. Reivindicación 1: Un compuesto de la fórmula (1), en donde: R1 es arilo, alquilo C1-6-arilo, alquilo C1-6-S(O)n-arilo, alquilo C1-5-O-arilo; o y en donde R1 está sin sustituir o sustituido independientemente con 1-3 R3; cada R3 se selecciona independientemente de H, halo, CN, alquilo C1-6, cicloalquilo C3-6, -OR4, alquilo C1-10-O-R4, -CO2R5, alquilo C1-10-CO2R5, N(R6)(R7), alquilo C1-10-N(R6)(R7), CON(R6)(R7), alquilo C1-10-CON(R6)(R7), -S(O)nR8, alquilo C1-10-S-(O)nR8, -S(O)n(R9)(R10), alquilo C1-10-S(O)nN(R9)(R10), arilo, -O-arilo, heteroarilo, -O-heteroarilo, alquilo C1-6-arilo, alquilo C1-6-heteroarilo, radical-C(O)-heterocíclico, radical alquilo C1-10-C(O)-heterocíclico, o haloalquilo C1-6; R2 es H, alquilo C1-10, cicloalquilo C3-6, haloalquilo C1-10, arilo, heteroarilo, alquilo C1-6-arilo, alquilo C1-5-O-arilo, alquilo C1-6-heteroarilo, alquilo C1-5-O-heteroarilo, alquilo C1-10-OR4, alquilo C1-10-CO2R5, alquilo C1-10-N(R6)(R7), alquilo C1-10-CON(R6)(R7), alquilo C1-10-S(O)nR8, alquilo C1-10-S(O)nN(R9)(R10), o radical alquilo C1-10-C(O)-heterocíclico; cada R4 se selecciona independientemente de H, alquilo C1-6, cicloalquilo C3-6, alquilo C1-9-CO2R5, alquilo C1-9-N(R6)(R7), alquilo C1-9-CON(R6)(R7), alquilo C1-9-S(O)nR8, o alquilo C1-9-S(O)nN(R9)(R10); cada R5 se selecciona independientemente de H, alquilo C1-6, cicloalquilo C3-6, o alquilo C1-6-arilo; cada R6 se selecciona independientemente de H, alquilo C1-6, arilo, heteroarilo, alquilo C1-6-arilo, alquilo C1-6-heteroarilo, -C(O)-alquiloC1-6, -C(O)-arilo, -C(O)-alquilo C1-6-arilo, -C(O)-heteroarilo, -C(O)-alquilo C1-6-heteroarilo, -C(NH)NH2, -S(O)n-R8, o alquilo C1-6-CO2R5; cada R7 se selecciona independientemente de H, alquilo C1-6, arilo o heteroarilo; cada R8 se selecciona independientemente de alquilo C1-6, arilo o heteroarilo; cada R9 se selecciona independientemente de H, alquilo C1-6, alquilo C1-6-arilo, alquilo C1-6-heteroarilo, -C(O)-alquilo C1-6, -C(O)-arilo, -C(O)-alquilo C1-6-arilo, -C(O)-alquilo C1-6-heteroarilo, arilo, o heteroarilo; cada R10 se selecciona independientemente de H, alquilo C1-6, alquilo C1-6-arilo, alquilo C1-6-heteroarilo, arilo o heteroarilo; R11 es H, arilo, heteroarilo, alquilo C1-6-heteroarilo, cicloalquilo C3-6, alquilo C1-6, alquilo C1-6-arilo, alquilo C1-6-CO2R5, o alquilo C1-6-N(R6)(R7); R12 es H, alquilo C1-6, arilo o heteroarilo; R13 es H, alquilo C1-6, arilo, o heteroarilo; B1 se selecciona del grupo de fórmulas (2) y n es 0, 1 ó 2; o una sal o solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33967401P | 2001-12-12 | 2001-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037770A1 true AR037770A1 (es) | 2004-12-01 |
Family
ID=23330105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104777A AR037770A1 (es) | 2001-12-12 | 2002-12-10 | Compuesto inhibidor de la integrasa del vih, composicion farmaceutica que lo comprende y uso del mismo para prepararla |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6777440B2 (es) |
| EP (1) | EP1467695A2 (es) |
| JP (1) | JP2005515206A (es) |
| KR (1) | KR20040065251A (es) |
| CN (1) | CN1617849A (es) |
| AR (1) | AR037770A1 (es) |
| AU (1) | AU2002366604A1 (es) |
| BR (1) | BR0214842A (es) |
| CA (1) | CA2469592C (es) |
| CO (1) | CO5590909A2 (es) |
| HR (1) | HRP20040534A2 (es) |
| HU (1) | HUP0402675A2 (es) |
| IL (1) | IL162325A0 (es) |
| IS (1) | IS7305A (es) |
| MX (1) | MXPA04005623A (es) |
| NO (1) | NO20042916L (es) |
| NZ (1) | NZ533413A (es) |
| PE (1) | PE20030763A1 (es) |
| PL (1) | PL370664A1 (es) |
| RU (1) | RU2284315C2 (es) |
| TW (1) | TWI252757B (es) |
| UY (1) | UY27577A1 (es) |
| WO (1) | WO2003049690A2 (es) |
| ZA (1) | ZA200404628B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7169932B2 (en) | 2001-06-11 | 2007-01-30 | Pfizer Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis |
| US7094909B2 (en) | 2001-06-11 | 2006-08-22 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
| PA8586801A1 (es) | 2002-10-31 | 2005-02-04 | Pfizer | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso |
| BRPI0407052A (pt) | 2003-01-27 | 2006-01-17 | Pfizer | Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização |
| US6890942B2 (en) * | 2003-05-16 | 2005-05-10 | Bristol-Myers Squibb Company | Acyl sulfonamides as inhibitors of HIV integrase |
| US20050215544A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
| US7776863B2 (en) * | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
| EP1751157B1 (en) | 2004-04-26 | 2007-10-03 | Pfizer Inc. | Inhibitors of the hiv integrase enzyme |
| CA2564356A1 (en) | 2004-04-26 | 2005-11-03 | Pfizer Inc. | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
| US7507838B2 (en) * | 2004-09-01 | 2009-03-24 | Bristol-Myers Squibb Company | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤 |
| WO2008004100A2 (en) | 2006-07-05 | 2008-01-10 | Pfizer Products Inc. | Therapeutic compounds |
| SI2364293T1 (sl) * | 2008-12-05 | 2013-05-31 | Syngenta Participations Ag | Novi pirazol-4-N-alkoksikarboksamidi kot mikrobiocidi |
| SG10201408512RA (en) | 2009-12-23 | 2015-02-27 | Univ Leuven Kath | Novel antiviral compounds |
| US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
| WO2012066442A1 (en) | 2010-11-15 | 2012-05-24 | Pfizer Limited | Inhibitors of hiv replication |
| BR112013011737A2 (pt) | 2010-11-15 | 2016-08-09 | Univ Leuven Kath | composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv |
| IN2014DN09934A (es) * | 2012-04-26 | 2015-08-14 | Bayer Cropscience Ag |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1082121A4 (en) * | 1998-06-03 | 2003-02-05 | Merck & Co Inc | HIV integrase |
| US6380249B1 (en) * | 1998-06-03 | 2002-04-30 | Merck & Co., Inc. | HIV integrase inhibitors |
| AR029304A1 (es) * | 1998-06-26 | 2003-06-25 | Daiichi Seiyaku Co | DERIVADOS DE PROPIONILO SUSTITUIDOS, PRODUCTO FARMACEUTICO, USO PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA PARA LA PREVENCION Y/O TRATAMIENTO DE HIPERCOLESTEROLEMIA, HIPERLIPEMIA O ARTERIOESCLEROSIS, COMPOSICIoN FARMACÉUTICA Y COMPUESTOS INTERMEDIARIOS |
-
2002
- 2002-12-06 PL PL02370664A patent/PL370664A1/xx not_active Application Discontinuation
- 2002-12-06 MX MXPA04005623A patent/MXPA04005623A/es unknown
- 2002-12-06 JP JP2003550741A patent/JP2005515206A/ja not_active Withdrawn
- 2002-12-06 CN CNA028279700A patent/CN1617849A/zh active Pending
- 2002-12-06 US US10/313,058 patent/US6777440B2/en not_active Expired - Lifetime
- 2002-12-06 WO PCT/US2002/039092 patent/WO2003049690A2/en not_active Ceased
- 2002-12-06 BR BR0214842-0A patent/BR0214842A/pt not_active IP Right Cessation
- 2002-12-06 EP EP02804741A patent/EP1467695A2/en not_active Withdrawn
- 2002-12-06 HR HR20040534A patent/HRP20040534A2/hr not_active Application Discontinuation
- 2002-12-06 NZ NZ533413A patent/NZ533413A/en unknown
- 2002-12-06 TW TW091135471A patent/TWI252757B/zh not_active IP Right Cessation
- 2002-12-06 RU RU2004119963/04A patent/RU2284315C2/ru not_active IP Right Cessation
- 2002-12-06 HU HU0402675A patent/HUP0402675A2/hu unknown
- 2002-12-06 KR KR10-2004-7009018A patent/KR20040065251A/ko not_active Ceased
- 2002-12-06 AU AU2002366604A patent/AU2002366604A1/en not_active Abandoned
- 2002-12-06 IL IL16232502A patent/IL162325A0/xx unknown
- 2002-12-06 CA CA002469592A patent/CA2469592C/en not_active Expired - Fee Related
- 2002-12-10 AR ARP020104777A patent/AR037770A1/es not_active Application Discontinuation
- 2002-12-11 UY UY27577A patent/UY27577A1/es not_active Application Discontinuation
- 2002-12-12 PE PE2002001198A patent/PE20030763A1/es not_active Application Discontinuation
-
2004
- 2004-06-09 CO CO04054295A patent/CO5590909A2/es not_active Application Discontinuation
- 2004-06-10 IS IS7305A patent/IS7305A/is unknown
- 2004-06-10 ZA ZA200404628A patent/ZA200404628B/en unknown
- 2004-07-09 NO NO20042916A patent/NO20042916L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2284315C2 (ru) | 2006-09-27 |
| PL370664A1 (en) | 2005-05-30 |
| WO2003049690A3 (en) | 2004-01-22 |
| WO2003049690A2 (en) | 2003-06-19 |
| BR0214842A (pt) | 2005-01-11 |
| EP1467695A2 (en) | 2004-10-20 |
| NO20042916L (no) | 2004-09-10 |
| HUP0402675A2 (hu) | 2005-03-29 |
| CO5590909A2 (es) | 2005-12-30 |
| RU2004119963A (ru) | 2006-01-10 |
| UY27577A1 (es) | 2003-07-31 |
| NZ533413A (en) | 2006-09-29 |
| JP2005515206A (ja) | 2005-05-26 |
| MXPA04005623A (es) | 2004-12-06 |
| AU2002366604A1 (en) | 2003-06-23 |
| CA2469592A1 (en) | 2003-06-19 |
| PE20030763A1 (es) | 2003-09-13 |
| US20030176495A1 (en) | 2003-09-18 |
| TWI252757B (en) | 2006-04-11 |
| KR20040065251A (ko) | 2004-07-21 |
| IS7305A (is) | 2004-06-10 |
| US6777440B2 (en) | 2004-08-17 |
| TW200301105A (en) | 2003-07-01 |
| ZA200404628B (en) | 2005-09-01 |
| IL162325A0 (en) | 2005-11-20 |
| HRP20040534A2 (en) | 2005-04-30 |
| CA2469592C (en) | 2005-08-23 |
| CN1617849A (zh) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037770A1 (es) | Compuesto inhibidor de la integrasa del vih, composicion farmaceutica que lo comprende y uso del mismo para prepararla | |
| PE20241341A1 (es) | Compuestos terapeuticos para la infeccion por el virus vih | |
| AR046202A1 (es) | Compuestos nucleosidicos para el tratamiento de infecciones virales | |
| JPWO2019155399A5 (es) | ||
| DK1353911T3 (da) | Antivirale midler | |
| EA200400585A1 (ru) | N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы | |
| BRPI0410714B8 (pt) | derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso | |
| MA31894B1 (fr) | Composes organiques | |
| AR038823A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
| HUP0004076A2 (hu) | C-4"-Szubsztituált-makrolid-származékok | |
| EA200400616A1 (ru) | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β | |
| EP1389463A4 (en) | MEDICAMENT FOR INHIBITING A DRUG REMOVAL PUMP | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| EA200400615A1 (ru) | Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| BRPI0418127A (pt) | uso de um composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, método para o tratamento de infecções envolvendo vìrus da sub-famìlia pneumovirinae, formulação farmacêutica, métodos para tratar mamìferos infectados e para prevenir a infecção de mamìferos com vìrus da sub-famìlia pneumovirinae, composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, composto e a forma n-óxido e sal piridìnio do mesmo, e, método de separação de enantiÈmeros de um composto | |
| MA27365A1 (fr) | Derives de spiro-indolinepiperidine | |
| EA200600225A1 (ru) | Производные пиперазина для лечения вич инфекций | |
| BR0316771A (pt) | Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica | |
| BR0015056A (pt) | Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico | |
| ATE332301T1 (de) | Antivirale pyrazolopyridin verbindungen | |
| NO20040881L (no) | Orale antidiabetes midler. | |
| RU2015122032A (ru) | Оксазолидинонсодержащие соединения, композиции и способы их использования | |
| DE60214401D1 (de) | Hetero-bicyclische crf antagonisten | |
| PE20232046A1 (es) | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |